[Prediction of the recurrence of squamous cell carcinoma of the uterine cervix by monitoring serum TA-4].
In this study, serum TA-4 and CEA in 21 recurrent cases were examined in relation to the pretreatment levels and recurrent lesions. The positive serum rate on recurrence was 66.7% in TA-4, 23.8% in CEA, and the mean serum level was 22.2 +/- 38.2 ng/ml in TA-4, while 4.8 +/- 9.2 ng/ml in CEA. In cases with local and intrapelvic recurrence, the positive serum rate was 61.5% in TA-4, 15.4% in CEA, and the mean serum level was 9.4 +/- 12.1 ng/ml in TA-4, and 4.3 +/- 10.2 ng/ml in CEA. In the cases in which there was distant recurrence, the serum positive rate was 75.0% in TA-4, 37.5% in CEA, and the mean serum level was 43.1 +/- 55.7 ng/ml in TA-4 and 5.7 +/- 7.7 ng/ml in CEA. In the cases whose serum pretreatment levels were positive, the positive serum rate on recurrence was 100% in TA-4 and 40.0% in CEA, while in the cases whose serum pretreatment levels were negative, the positive serum rate on recurrence was 40.0% in TA-4 and 9.1% in CEA. In 61.9% of the recurrent cases, the increase in serum TA-4 preceded the appearance of clinical signs, while the increase in serum CEA preceded it in only 19.0% of the recurrent cases. The mean leading time for tumor markers in the diagnosis of recurrence was 77.9 days in TA-4 and 60.0 days in CEA. It is therefore concluded that serum TA-4 monitoring after treatment is able to be used in predicting the recurrence of squamous cell carcinoma of the uterine cervix.
D000951:Antigens, Neoplasm / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis*; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis*
D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; C036649:tumor antigen TA-4, human